Effects of a new compound containing Palmitoylethanolamide and Baicalein in myocardial ischaemia/reperfusion injury in vivo
Laboratory studyOther animalsWith baicalein
This study tested palmitoylethanolamide together with baicalein. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Laboratory study
- Subjects
- Animals (species not stated in the abstract) with myocardial ischaemia/reperfusion injury from 30 minutes of coronary artery occlusion followed by 2 hours of reperfusion
- Dose used in the study
- PEA-baicalein composite (9:1), 10 mg/kg, given 5 minutes before the end of ischaemia and again 1 hour after reperfusion
- Duration
- 30 minutes ischaemia plus 2 hours reperfusion
- What was measured
- Myocardial tissue injury, neutrophil infiltration, mast cell activation markers (chymase, tryptase), cytokines (TNF-alpha, IL-1beta), oxidative stress, and NF-kB and apoptosis pathways
What the authors reported
PEA-baicalein treatment reduced myocardial tissue injury, neutrophil infiltration, chymase and tryptase expression, and TNF-alpha and IL-1beta production. It also reduced oxidative stress and modulated NF-kB and apoptosis pathway activity. PEA-Baicalein (9:1) was given at 10 mg/kg, 5 minutes before the end of ischaemia and again 1 hour after reperfusion.
Limits of this study
An animal model of induced heart injury; it cannot show effect in people. Funding and conflicts not stated in the abstract. PubMed lists an erratum for this paper (Phytomedicine. 2023 Feb;110:154592).
Source
PubMed 30668378 · doi:10.1016/j.phymed.2018.09.191
Entry checked against the abstract on PubMed on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.